A New Name for Acomplia?
This article was originally published in RPM Report
Executive Summary
Sanofi-Aventis is facing a possible name change for rimonabant in the US market. For a much-anticipated primary care product like Acomplia, that's not good news. Sanofi has sent mixed signals as to whether FDA will accept "Acomplia" as the brand name for rimonabant, but all signs indicate that the company will have to choose an alternate name for the US market.
You may also be interested in...
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.
US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’
Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.